Ftse Mib
34.603,61
0,00%
DAX
18.726,76
-0,21%
S&P 500
5.321,41
0,25%
NASDAQ
16.832,62
0,22%
Bitcoin
69.879,07
-0,36%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Canada TSX Knight Therapeutics Inc (GUD) Knight Therapeutics Inc (GUD) Notizie

GUD

Knight Therapeutics (GUD)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:TSX:GUD
DataOraFonteTitoloSimboloCompagnia
10/08/202317:00AllPennyStocks.comTrading For This Specialty Pharma Company is up Following Second Quarter ResultsTSX:GUDKnight Therapeutics Inc
13/05/202115:38PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - GUDTSX:GUDKnight Therapeutics Inc
13/05/202115:37PR Newswire (Canada)IIROC Trade Resumption - GUDTSX:GUDKnight Therapeutics Inc
13/05/202114:25PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - GUDTSX:GUDKnight Therapeutics Inc
13/05/202114:24PR Newswire (Canada)IIROC Trading Halt - GUDTSX:GUDKnight Therapeutics Inc
03/05/202112:00PR Newswire (Canada)Maverix Private Equity Announces Team AdditionsTSX:GUDKnight Therapeutics Inc
11/12/202023:15PR Newswire (Canada)S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite IndexTSX:GUDKnight Therapeutics Inc
11/12/202023:15PR Newswire (Canada)S&P Dow Jones Indices annonce des modifications à l'indice composé S&P/TSXTSX:GUDKnight Therapeutics Inc
08/01/202014:00PR Newswire (US)Knight Partners With Debiopharm for the Commercialization of Trelstar® in CanadaTSX:GUDKnight Therapeutics Inc
18/06/201923:00PR Newswire (US)Medimetriks Pharmaceuticals Focuses on Advancing MM36 (difamilast) Through Phase 3 Trials; Extinguishes Debt Owed to Knight T...TSX:GUDKnight Therapeutics Inc
29/04/201914:45PR Newswire (Canada)Medison Urges Fellow Shareholders to Bring Positive Change to Knight Therapeutics by Voting for All Six of Medison's Highly Q...TSX:GUDKnight Therapeutics Inc
25/04/201916:21PR Newswire (Canada)Leading Independent Proxy Advisory Firm ISS Recommends Change at Knight TherapeuticsTSX:GUDKnight Therapeutics Inc
18/04/201915:00PR Newswire (Canada)Medison Issues Presentation to Knight ShareholdersTSX:GUDKnight Therapeutics Inc
17/04/201913:00PR Newswire (Canada)Leading Canadian Corporate Governance Expert Confirms Acute Board Conflicts and Governance Deficiencies at Knight Therapeutic...TSX:GUDKnight Therapeutics Inc
16/04/201914:30PR Newswire (Canada)Medison Issues Letter to Shareholders of Knight Therapeutics, Outlining Qualified, Independent Director Nominees and Common-S...TSX:GUDKnight Therapeutics Inc
10/04/201914:39PR Newswire (Canada)Medison Disappointed that Knight Therapeutics has Resorted to Blatant Misrepresentations to Avoid ScrutinyTSX:GUDKnight Therapeutics Inc
08/04/201914:00PR Newswire (Canada)Medison Files Proxy Circular, Offers Knight Therapeutics Shareholders Truly Independent, Unconflicted Directors and Comprehen...TSX:GUDKnight Therapeutics Inc
01/04/201914:00PR Newswire (Canada)Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Cre...TSX:GUDKnight Therapeutics Inc
18/02/201914:30PR Newswire (US)Knight Signs GUD (Bueno) Latin American Strategic Funding Deal with Moksha8TSX:GUDKnight Therapeutics Inc
19/03/201811:30PR Newswire (US)Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in CanadaTSX:GUDKnight Therapeutics Inc
08/02/201815:21PR Newswire (US)60° Pharmaceuticals (60P) Receives Priority Review Designation For Malaria DrugTSX:GUDKnight Therapeutics Inc
04/01/201815:45PR Newswire (US)60 Degrees Pharmaceuticals Fast Tracked For Malaria DrugTSX:GUDKnight Therapeutics Inc
18/12/201715:00PR Newswire (US)60° Pharmaceuticals (60P) Submits New Drug Application to US FDA for Antimalarial Drug TafenoquineTSX:GUDKnight Therapeutics Inc
14/08/201723:30MarketwiredSynergy CHC Corp. Announces Second Quarter 2017 ResultsTSX:GUDKnight Therapeutics Inc
13/06/201714:03PR Newswire (Canada)Braeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE® in Canada for Opioid...TSX:GUDKnight Therapeutics Inc
10/12/201600:17PR Newswire (Canada)Indices S&P Dow Jones annonce des modifications à certains indices canadiens S&P/TSXTSX:GUDKnight Therapeutics Inc
22/03/201612:59PR Newswire (US)Profounda, Inc. launches Impavido® (miltefosine), the first and only oral Rx treatment for visceral, mucosal and cutaneous l...TSX:GUDKnight Therapeutics Inc
17/02/201614:54PR Newswire (US)Knight Breaks Glass on Medimetriks PartnershipTSX:GUDKnight Therapeutics Inc
01/02/201614:00PR Newswire (US)Braeburn Pharmaceuticals and Knight Therapeutics Announce Canadian Sublicense Agreement for PROBUPHINE®TSX:GUDKnight Therapeutics Inc
11/09/201523:15PR Newswire (Canada)S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian IndicesTSX:GUDKnight Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:TSX:GUD

La tua Cronologia

COIN
PLCETH
LSE
SL85
Citi Fun 25
UNSW3
OVRETH
OVR
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network